CN111065630A - 一种内磺酰胺化合物结晶 - Google Patents

一种内磺酰胺化合物结晶 Download PDF

Info

Publication number
CN111065630A
CN111065630A CN201880059881.0A CN201880059881A CN111065630A CN 111065630 A CN111065630 A CN 111065630A CN 201880059881 A CN201880059881 A CN 201880059881A CN 111065630 A CN111065630 A CN 111065630A
Authority
CN
China
Prior art keywords
formula
compound
crystalline
monohydrate
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880059881.0A
Other languages
English (en)
Other versions
CN111065630B (zh
Inventor
张喜全
徐文卫
李明明
孔敏敏
吴叔峰
张爱明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centaurus Biopharma Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Original Assignee
Centaurus Biopharma Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centaurus Biopharma Co Ltd, Chia Tai Tianqing Pharmaceutical Group Co Ltd, Lianyungang Runzhong Pharmaceutical Co Ltd filed Critical Centaurus Biopharma Co Ltd
Publication of CN111065630A publication Critical patent/CN111065630A/zh
Application granted granted Critical
Publication of CN111065630B publication Critical patent/CN111065630B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

本申请涉及一种内磺酰胺化合物结晶，具体涉及(S)‑N‑((S)‑1‑(2‑氯苯基)‑2‑((3,3‑二氟环丁基)氨基)‑2‑氧代乙基)‑2‑(4‑氰基吡啶‑2‑基)‑N‑(3‑氟苯基)‑异噻唑烷‑3‑甲酰胺1,1‑二氧化物结晶、其制备方法、其结晶组合物、药物组合物及其用途。本申请式Ⅱ的一水合物结晶的X‑射线粉末衍射光谱用2θ值表示在约14.40°、20.28°、20.94°、22.02°和24.46°处有衍射峰。本申请式Ⅱ的一水合物结晶具有较好的IDH1抑制活性，且该结晶表现出较高的稳定性，在物理性质、安全性及代谢稳定性方面具备优势，有较高的成药价值。

Description

PCT国内申请，说明书已公开。

Claims (25)

  1. PCT国内申请，权利要求书已公开。
CN201880059881.0A 2017-09-22 2018-09-21 一种内磺酰胺化合物结晶 Active CN111065630B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017108639248 2017-09-22
CN201710863924 2017-09-22
PCT/CN2018/106889 WO2019057142A1 (zh) 2017-09-22 2018-09-21 一种内磺酰胺化合物结晶

Publications (2)

Publication Number Publication Date
CN111065630A true CN111065630A (zh) 2020-04-24
CN111065630B CN111065630B (zh) 2022-12-30

Family

ID=65810104

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880059881.0A Active CN111065630B (zh) 2017-09-22 2018-09-21 一种内磺酰胺化合物结晶

Country Status (11)

Country Link
US (1) US11254665B2 (zh)
EP (1) EP3686191B1 (zh)
JP (1) JP6951562B2 (zh)
KR (1) KR102707847B1 (zh)
CN (1) CN111065630B (zh)
AU (1) AU2018337153B2 (zh)
CA (1) CA3076405A1 (zh)
FI (1) FI3686191T3 (zh)
HU (1) HUE061207T2 (zh)
PL (1) PL3686191T3 (zh)
WO (1) WO2019057142A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023226964A1 (en) * 2022-05-26 2023-11-30 Danatlas Pharmaceuticals Co., Ltd. Heterocyclic derivatives, compositions and uses thereof
WO2024131727A1 (zh) * 2022-12-19 2024-06-27 正大天晴药业集团股份有限公司 一种内磺酰胺化合物治疗胆道癌的用途
WO2024205311A1 (en) * 2023-03-31 2024-10-03 Avelos Therapeutics Inc. Substituted sultam compound derivatives and their pharmaceutical use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103097340A (zh) * 2010-07-16 2013-05-08 安吉奥斯医药品有限公司 治疗活性组合物及其使用方法
WO2015010297A1 (en) * 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN109071471B (zh) * 2016-03-22 2021-05-07 正大天晴药业集团股份有限公司 内磺酰胺化合物及其使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX350432B (es) * 2012-01-19 2017-09-06 Agios Pharmaceuticals Inc Compuestos terapeuticamente activos y sus metodos de empleo.
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
JP6524119B2 (ja) * 2014-03-14 2019-06-05 アジオス ファーマシューティカルズ， インコーポレイテッド 治療活性化合物の医薬組成物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103097340A (zh) * 2010-07-16 2013-05-08 安吉奥斯医药品有限公司 治疗活性组合物及其使用方法
WO2015010297A1 (en) * 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN109071471B (zh) * 2016-03-22 2021-05-07 正大天晴药业集团股份有限公司 内磺酰胺化合物及其使用方法

Also Published As

Publication number Publication date
CN111065630B (zh) 2022-12-30
AU2018337153B2 (en) 2022-10-20
KR20200057049A (ko) 2020-05-25
JP6951562B2 (ja) 2021-10-20
US20200291012A1 (en) 2020-09-17
HUE061207T2 (hu) 2023-05-28
EP3686191A1 (en) 2020-07-29
WO2019057142A1 (zh) 2019-03-28
JP2020534301A (ja) 2020-11-26
CA3076405A1 (en) 2019-03-28
US11254665B2 (en) 2022-02-22
PL3686191T3 (pl) 2023-03-06
KR102707847B1 (ko) 2024-09-23
EP3686191A4 (en) 2021-01-20
EP3686191B1 (en) 2022-12-14
FI3686191T3 (fi) 2023-01-31
AU2018337153A1 (en) 2020-04-09

Similar Documents

Publication Publication Date Title
US11773079B2 (en) Crystalline forms of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine
CN111065630B (zh) 一种内磺酰胺化合物结晶
CN109689641B (zh) 一种取代的2-氢-吡唑衍生物的晶型、盐型及其制备方法
US20110021547A1 (en) Substantially Pure and a Stable Crystalline Form of Bosentan
CN109071471B (zh) 内磺酰胺化合物及其使用方法
US11053261B2 (en) Solid state forms of ixazomib citrate
CN115427397B (zh) 硝羟喹啉前药的晶型、含其的药物组合物及其制备方法和应用
CN117769560A (zh) Egfr抑制剂的盐、晶型及其组合物和应用
CA3222612A1 (en) New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide
CN115052874A (zh) 一种作用于crbn蛋白的三并环类化合物的结晶及其制备方法
CN114222745A (zh) 活化素受体样激酶抑制剂的盐和晶体形式
US10221185B2 (en) Crystal form of substituted aminopyran derivativek
CN112125910A (zh) 一种阿伐普替尼晶型及其制备方法
EP4438600A1 (en) Compound used as kinase inhibitor and use thereof
CN111263763B (zh) 一种三并环化合物的结晶
WO2021104186A1 (en) Novel salts of indoleamine 2,3-dioxygenase inhibitors
CN116514796A (zh) 3CLpro蛋白酶抑制剂的盐、晶型及其制备方法
CN117794913A (zh) 嘧啶衍生物及其药学上可接受的盐的多晶型物和应用
CN113045490A (zh) 结晶型硝羟喹啉及其制备方法和用途
CN117417336A (zh) 一种替沃扎尼对甲苯磺酸盐的晶型及其制备方法和应用
WO2014143617A1 (en) Deuterium-enriched tanaproget and processes for its preparation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40027070

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant